Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 5, 2015, Pages 900-908

  Karrar, Azza ^a   Stepanova, Maria ^b   Alaparthi, Lakshmi ^b   Lingam, Sneha ^a   Younoszai, Zahra ^a   Zheng, Li ^a   Malik, Khatera S ^a   Younossi, Elena ^a   Monge, Fanny ^b   Hunt, Sharon L ^a   Goodman, Zachary ^a,b   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Antibodies; Humoral immune response; NAFLD; NASH; Steatohepatitis

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; AUTOANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK ASSESSMENT; ADIPOCYTE; ANALYSIS OF VARIANCE; BLOOD; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; MIDDLE AGED; PHYSIOLOGY; RISK;

ADIPOCYTES; ADULT; ANALYSIS OF VARIANCE; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOMODULATION; INFLAMMATION; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK;

EID: 84926622021     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12856     Document Type: Article

References (29)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-438.
2. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
3. Younossi ZM, Stepanova M, Afendy M etal. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011; 9: 524-530 e1; quiz e60.
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003; 112: 1796-1808.
5. Kintscher U, Hartge M, Hess K etal. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler. Thromb. Vasc. Biol. 2008; 28: 1304-1310.
6. Murano I, Barbatelli G, Parisani V etal. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J. Lipid Res. 2008; 49: 1562-1568.
7. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am. J. Gastroenterol. 2004; 99: 1316-1320.
8. Niwa H, Sasaki M, Haratake J etal. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol. Res. 2007; 37: 923-931.
9. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
10. Loria P, Lonardo A, Leonardi F etal. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig. Dis. Sci. 2003; 48: 2173-2181.
11. Loria P, Carulli N, Lonardo A. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005; 100: 1200-1201; author reply 1-2.
12. Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 2004; 38: 801-804.
13. Vuppalanchi R, Gould RJ, Wilson LA etal. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol. Int. 2012; 6: 379-385.
14. Tsuneyama K, Baba H, Kikuchi K etal. Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin. Rev. Allergy Immunol. 2013; 45: 143-148.
15. Younossi ZM, Stepanova M, Rafiq N etal. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-1882.
16. Goodman ZD. The impact of obesity on liver histology. Clin. Liver Dis. 2014; 18: 33-40.
17. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler. Thromb. Vasc. Biol. 2001; 21: 101-107.
18. Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin. Chem. Lab. Med. 2014; 52: 1695-1727.
19. Kyaw T, Tipping P, Bobik A, Toh BH. Protective role of natural IgM-producing B1a cells in atherosclerosis. Trends Cardiovasc. Med. 2012; 22: 48-53.
20. Kyaw T, Tay C, Krishnamurthi S etal. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ. Res. 2011; 109: 830-840.
21. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120: 417-426.
22. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin. Immunol. 2010; 134: 47-54.
23. Su J, Hua X, Concha H, Svenungsson E, Cederholm A, Frostegard J. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology 2008; 47: 1144-1150.
24. Obukhanych TV, Nussenzweig MC. T-independent type II immune responses generate memory B cells. J. Exp. Med. 2006; 203: 305-310.
25. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J. Hepatol. 2008; 48: 821-828.
26. Day CP. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002; 16: 663-678.
27. Day CP, James OF. Steatohepatitis: a tale of two "hits." Gastroenterology 1998; 114: 842-845.
28. Poynard T, Ratziu V, McHutchison J etal. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
29. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.